Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
4.780
+0.130 (2.80%)
At close: Jul 1, 2026, 4:00 PM EDT
4.690
-0.090 (-1.88%)
After-hours: Jul 1, 2026, 4:20 PM EDT
Atea Pharmaceuticals Employees
Atea Pharmaceuticals had 55 employees as of December 31, 2025. The number of employees decreased by 1 or -1.79% compared to the previous year.
Employees
55
Change (1Y)
-1
Growth (1Y)
-1.79%
Revenue / Employee
n/a
Profits / Employee
-$3,082,127
Market Cap
382.53M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 55 | -1 | -1.79% |
| Dec 31, 2024 | 56 | -19 | -25.33% |
| Sep 30, 2024 | 75 | 1 | 1.35% |
| Jun 30, 2024 | 75 | 3 | 4.17% |
| Mar 31, 2024 | 74 | 1 | 1.37% |
| Dec 31, 2023 | 75 | 5 | 7.14% |
| Sep 30, 2023 | 74 | 6 | 8.82% |
| Jun 30, 2023 | 72 | 9 | 14.29% |
| Mar 31, 2023 | 73 | 9 | 14.06% |
| Dec 31, 2022 | 70 | 11 | 18.64% |
| Sep 30, 2022 | 68 | 12 | 21.43% |
| Jun 30, 2022 | 63 | 14 | 28.57% |
| Mar 31, 2022 | 64 | 22 | 52.38% |
| Dec 31, 2021 | 59 | 20 | 51.28% |
| Sep 30, 2021 | 56 | 45 | 409.09% |
| Jun 30, 2021 | 49 | 38 | 345.45% |
| Mar 31, 2021 | 42 | 31 | 281.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Abeona Therapeutics | 226 |
| Rocket Pharmaceuticals | 202 |
| OmniAb | 89 |
| Upstream Bio | 75 |
| Cybin | 50 |
| X4 Pharmaceuticals | 45 |
| Compass Therapeutics | 39 |
AVIR News
- 6 days ago - Atea Pharmaceuticals completes patient enrollment in C-FORWARD trial - TheFly
- 6 days ago - Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - GlobeNewsWire
- 13 days ago - Atea Pharmaceuticals Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026 - GlobeNewsWire
- 7 weeks ago - Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline - GlobeNewsWire
- 7 weeks ago - Atea Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 7 weeks ago - Atea Pharmaceuticals Slides: Q1 2026 - Filings
- 7 weeks ago - Atea Pharmaceuticals Earnings release: Q1 2026 - Filings